バイオマニュファクチャリングの世界市場

バイオマニュファクチャリングの世界市場は2030年までに315億米ドルに達する見込み

2024年に215億米ドルと推定されるバイオマニュファクチャリングの世界市場は、2024年から2030年にかけてCAGR 6.6%で成長し、2030年には315億米ドルに達すると予測されます。本レポートで分析されているセグメントの一つである連続アップストリームバイオマニュファクチャリングは、CAGR 7.9%を記録し、分析期間終了時には190億米ドルに達すると予測されています。シングルユース上流バイオマニュファクチャリングセグメントの成長率は、分析期間でCAGR 4.6％と推定されます。

米国市場は59億米ドル、中国はCAGR 10.6％で成長予測

米国のバイオマニュファクチャリング市場は、2024年に59億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024年から2030年にかけてCAGR 10.6%で推移し、2030年には市場規模が66億米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.2%と6.5%と予測されています。欧州では、ドイツがCAGR 4.4%で成長すると予測されています。

世界のバイオマニュファクチャリング市場- 主要動向と促進要因のまとめ

バイオマニュファクチャリングが医薬品および工業生産の世界情勢を変える理由とは？

バイオマニュファクチャリングは、医薬品、バイオ燃料、工業用酵素、食品成分、バイオマテリアルなどの幅広い製品を開発するために、生物、細胞、または生物学的システムを使用することで、現代の生産プロセスに革命を起こしています。高温、有毒な溶媒、化石由来のインプットに依存することが多い従来の化学製造とは異なり、バイオマニュファクチャリングは生物学に基づく、しばしば再生可能な方法を活用し、高い特異性と効率で複雑な分子を製造します。製薬分野では、バイオマニュファクチャリングはモノクローナル抗体、ワクチン、インスリンなどのホルモン、遺伝子治療や細胞治療などの生物製剤の製造において中心的な役割を果たしています。これらの治療法では、生きた細胞だけが提供できる精密なタンパク質構造や翻訳後修飾が必要とされることがよくあります。微生物発酵による肥料、藻類ベースのバイオ燃料、生分解性バイオポリマーといった持続可能な代替品を通じて、農業、エネルギー、繊維の分野にも変革をもたらしています。世界の産業界がカーボンフットプリントの削減と環境負荷の低減を目指している中、バイオマニュファクチャリングは、ESG目標や循環型経済モデルに沿った、よりクリーンで安全かつ持続可能な代替品を提供しています。バイオマニュファクチャリングは、ESG目標や循環型経済モデルに沿った、よりクリーンで、より安全で、より持続可能な選択肢を提供します。バイオマニュファクチャリングは、単に従来の生産をアップグレードするものではなく、Global Industry Analystsが未来の製造業をどのように構想し、設計し、規模を拡大するかという根本的な転換を意味するものです。

技術の進歩は、次世代のバイオマニュファクチャリングをどのように動かしているのでしょうか？

技術革新は、バイオマニュファクチャリングプロセスの可能性、精度、生産性を大幅に拡大しています。この進歩の中心となっているのが合成生物学であり、科学者は、より高い収量と標的特異性のために代謝経路を最適化するカスタムデザインの遺伝子設計図を持つ酵母、バクテリア、哺乳類細胞などの微生物を工学的に設計することができます。CRISPRやその他の遺伝子編集ツールは、以前は手間がかかり、予測不可能であった迅速で正確な改変を可能にします。一方、シングルユース・バイオリアクター、連続製造、灌流システムなどのバイオプロセス技術の進歩は、スケーラビリティを高め、製造コストを削減しています。デジタル化もまた、バイオマニュファクチャリングを変革しています。リアルタイムセンサー、データ分析、AIアルゴリズムを搭載したスマート工場は、かつてないレベルでの予知保全、プロセス最適化、品質保証を可能にしています。ロボット工学とデジタルツインによる自動化により、ハイスループット実験と製品開発サイクルの加速が可能になります。細胞培養培地、飼料戦略、上流／下流の統合における革新は、プロセスの歩留まりとバッチ間の一貫性を向上させています。さらに機械学習は、発酵結果のシミュレーション、タンパク質フォールディングの最適化、市場投入までの時間短縮に利用されています。クラウドベースのプラットフォームは現在、共同開発をサポートし、アカデミア、バイオテクノロジー新興企業、大手製薬会社の利害関係者がリアルタイムでデータを共有し、プロセスを改良することを可能にしています。これらのテクノロジーは総体として、バイオマニュファクチャリングを研究室の枠を超え、需要の変化や治療の複雑性に適応できるスケーラブルで効率的な産業グレードのオペレーションへと押し上げます。バイオマニュファクチャリングは、生物学、コンピューティング、エンジニアリングの融合が進む中、より速く、より安く、よりカスタマイズ可能な生産ソリューションを世界規模で提供できる体制を整えています。

バイオマニュファクチャリングの導入と拡大をリードしている分野と世界市場は？

バイオマニュファクチャリングの採用は、多様な産業と世界地域で加速しており、それぞれが特定の経済、ヘルスケア、環境ニーズに対応するためにその機能を活用しています。製薬・バイオテクノロジー分野では、米国や欧州の主要企業が生物製剤や個別化医療の需要拡大に対応するため、バイオマニュファクチャリングに多額の投資を行っています。ブロックバスター生物製剤が医薬品収益の大部分を占める中、ジェネンテック社、アムジェン社、ロシュ社などの企業は、自社および開発・製造受託機関（CDMO）を通じてバイオマニュファクチャリングの足跡を拡大しています。アジア太平洋では、中国、インド、韓国、シンガポールのような国々が、政府の優遇措置、熟練した労働力、ヘルスケア市場の拡大に支えられ、バイオマニュファクチャリングの能力を急速に拡大しています。例えば中国は、"Made in China 2025 "イニシアチブの下、バイオマニュファクチャリングを戦略的優先事項としています。食品と農業の分野では、代替タンパク質、酵素、バイオベースの保存料を生産するためにバイオマニュファクチャリングが採用され、植物由来の持続可能な食生活を求める世界の需要の高まりに対応しています。環境・エネルギー分野では、バイオ燃料や生分解性プラスチックを生産するために、微生物や藻類を利用したシステムが、特にグリーンテクノロジーへの投資が盛んな地域で活用されています。ラテンアメリカは、その広大なバイオマスの利用可能性と生物多様性を背景に、農業バイオマニュファクチャリングの重要な担い手として台頭し始めています。これらすべての地域で、バイオマニュファクチャリングは、バイオエコノミーの開発、イノベーションのエコシステム、産業の脱炭素化に焦点を当てた、より広範な国家戦略に統合されつつあります。このような多方面にわたる世界の推進により、バイオマニュファクチャリングは経済と環境に多大な影響を与える基盤産業へと変貌を遂げつつあります。

世界のバイオマニュファクチャリング市場の成長の原動力は？

世界のバイオマニュファクチャリング市場の成長は、ヘルスケア需要、環境への緊急性、技術の成熟度、支持的な政策枠組みなど、相互に関連するいくつかの要因によって牽引されています。最も顕著な原動力の一つは、モノクローナル抗体、遺伝子治療、mRNAワクチンのような複雑な治療薬を含む生物製剤に対する需要の急激な増加です。この需要は、世界の高齢化と、生物学的標的を用いた長期的な治療ソリューションを必要とする慢性疾患の罹患率の増加によって、さらに高まっています。COVID-19のパンデミックは、弾力性と拡張性のある能力の戦略的重要性を実証し、官民双方のインフラへの大規模な投資につながりました。また、環境維持の目標も、石油化学ベースの製造に代わるものを産業界が求める中、採用の原動力となっています。バイオマニュファクチャリングは、ネットゼロ目標や循環型経済モデルに沿った、低排出で廃棄物を最小限に抑える経路を提供します。規制面では、生物製剤とバイオシミラーの迅速な承認パスウェイが、政府の助成金や税制優遇措置とともに、新興企業の参入障壁を下げ、イノベーションを加速させています。自動化、プロセス制御、モジュール式設備設計の進歩は、市場投入までの時間を短縮し、大規模な需要にもニッチな需要にも対応できる柔軟な生産を可能にしています。さらに、学界、バイオテクノロジー企業、多国籍メーカー間の協力関係の強化は、イノベーション・クラスターを形成し、次世代プラットフォームの開発を加速させています。より多くの産業や政府が生物学的製造の戦略的価値を認識するにつれ、この分野への投資と技術革新は増加の一途をたどっています。その結果、生物学が産業の原動力となり、世界の生産規範を再定義する可能性を秘めた市場がダイナミックに拡大することになります。

セグメント

ワークフロー（連続的上流工程バイオマニュファクチャリング,単回使用上流工程バイオマニュファクチャリング,下流工程バイオマニュファクチャリング）;最終用途（バイオ製薬企業最終用途,研究機関最終用途, CMO/CDMO最終用途）;用途（モノクローナル抗体用途,ホルモン用途,ワクチン用途,組換えタンパク質用途,その他用途）

調査対象企業の例（注目の36社）

• AbbVie Inc.
• Amgen Inc.
• Biocon Limited
• BioNTech SE
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Catalent, Inc.
• Cytiva
• Eli Lilly and Company
• FUJIFILM Diosynth Biotechnologies
• Genentech, Inc.
• Ginkgo Bioworks Holdings, Inc.
• Lonza Group AG
• Moderna, Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Roche Holding AG
• Samsung Biologics Co., Ltd.
• WuXi Biologics

AIインテグレーション

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Biomanufacturing Market to Reach US$31.5 Billion by 2030

The global market for Biomanufacturing estimated at US$21.5 Billion in the year 2024, is expected to reach US$31.5 Billion by 2030, growing at a CAGR of 6.6% over the analysis period 2024-2030. Continuous Upstream Biomanufacturing, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$19.0 Billion by the end of the analysis period. Growth in the Single-Use Upstream Biomanufacturing segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.9 Billion While China is Forecast to Grow at 10.6% CAGR

The Biomanufacturing market in the U.S. is estimated at US$5.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.6 Billion by the year 2030 trailing a CAGR of 10.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Biomanufacturing Market - Key Trends & Drivers Summarized

Why Is Biomanufacturing Reshaping the Global Landscape of Pharmaceutical and Industrial Production?

Biomanufacturing is revolutionizing modern production processes by using living organisms, cells, or biological systems to develop a broad spectrum of products including pharmaceuticals, biofuels, industrial enzymes, food ingredients, and biomaterials. Unlike traditional chemical manufacturing that often relies on high temperatures, toxic solvents, and fossil-derived inputs, biomanufacturing leverages biologically-based and often renewable methods to produce complex molecules with high specificity and efficiency. In the pharmaceutical sector, biomanufacturing plays a central role in the production of biologics, including monoclonal antibodies, vaccines, hormones like insulin, and gene or cell therapies. These therapies often require precise protein structures and post-translational modifications that only living cells can provide. The value of biomanufacturing extends beyond healthcare-it is also transforming the agricultural, energy, and textile sectors through sustainable alternatives like microbial fermentation for fertilizers, algae-based biofuels, and biodegradable biopolymers. As global industries aim to lower carbon footprints and reduce environmental impact, biomanufacturing offers a cleaner, safer, and more sustainable alternative that aligns with ESG goals and circular economy models. Its ability to produce high-value, low-volume products with minimal waste and energy consumption is especially relevant in an era of increasing resource scarcity and climate consciousness. Biomanufacturing isn’t just an upgrade to traditional production-it represents a fundamental shift in how we conceptualize, design, and scale the manufacturing of the future.

How Are Technological Advancements Powering the Next Generation of Biomanufacturing?

Technological innovations are significantly expanding the potential, precision, and productivity of biomanufacturing processes. Central to this advancement is synthetic biology, which enables scientists to engineer microorganisms like yeast, bacteria, or mammalian cells with custom-designed genetic blueprints that optimize metabolic pathways for higher yield and target specificity. CRISPR and other gene-editing tools allow for rapid, precise modifications that were previously labor-intensive and unpredictable. Meanwhile, advances in bioprocessing technologies such as single-use bioreactors, continuous manufacturing, and perfusion systems are increasing scalability and reducing production costs. Digitalization is also transforming biomanufacturing-smart factories equipped with real-time sensors, data analytics, and AI algorithms enable predictive maintenance, process optimization, and quality assurance at unprecedented levels. Automation through robotics and digital twins allows for high-throughput experimentation and accelerated product development cycles. Innovations in cell culture media, feed strategies, and upstream/downstream integration have improved process yields and consistency across batches. Furthermore, machine learning is being used to simulate fermentation outcomes, optimize protein folding, and reduce time to market. Cloud-based platforms now support collaborative development, enabling stakeholders from academia, biotech startups, and big pharma to share data and refine processes in real time. These technologies collectively push biomanufacturing beyond laboratory confines into scalable, efficient, and industrial-grade operations that can adapt to evolving demand and therapeutic complexity. As innovation continues to converge across biology, computing, and engineering, biomanufacturing is positioned to deliver faster, cheaper, and more customizable production solutions on a global scale.

Which Sectors and Global Markets Are Leading the Adoption and Expansion of Biomanufacturing?

The adoption of biomanufacturing is accelerating across a diverse array of industries and global regions, each leveraging its capabilities to address specific economic, healthcare, and environmental needs. In the pharmaceutical and biotechnology sectors, leading companies in the United States and Europe are heavily investing in biomanufacturing to meet the growing demand for biologics and personalized medicine. With blockbuster biologics accounting for a significant portion of pharmaceutical revenues, companies like Genentech, Amgen, and Roche are expanding their biomanufacturing footprints both in-house and through contract development and manufacturing organizations (CDMOs). In Asia-Pacific, countries like China, India, South Korea, and Singapore are rapidly scaling up biomanufacturing capabilities, supported by government incentives, skilled labor, and expanding healthcare markets. China, for instance, is making biomanufacturing a strategic priority under its "Made in China 2025" initiative. The food and agriculture sectors are adopting biomanufacturing to produce alternative proteins, enzymes, and bio-based preservatives, catering to a growing global demand for plant-based and sustainable diets. Environmental and energy sectors are leveraging microbial and algae-based systems to generate biofuels and biodegradable plastics, especially in regions where green technology investment is high. Latin America is beginning to emerge as a key player in agricultural biomanufacturing, thanks to its vast biomass availability and biodiversity. In all these regions, biomanufacturing is being integrated into broader national strategies focused on bioeconomy development, innovation ecosystems, and industrial decarbonization. This multi-sectoral and global push is transforming biomanufacturing into a foundational industry with far-reaching economic and environmental impact.

What Is Fueling the Growth in the Global Biomanufacturing Market?

The growth in the global biomanufacturing market is driven by several interconnected factors related to healthcare demand, environmental urgency, technological maturity, and supportive policy frameworks. One of the most prominent drivers is the exponential rise in demand for biologics, including complex therapeutics like monoclonal antibodies, gene therapies, and mRNA vaccines. This demand is further amplified by the global aging population and the increasing incidence of chronic diseases that require long-term, biologically-targeted treatment solutions. The COVID-19 pandemic demonstrated the strategic importance of resilient and scalable biomanufacturing capacity, leading to massive investments in both public and private infrastructure. Environmental sustainability goals are also driving adoption, as industries seek alternatives to petrochemical-based manufacturing. Biomanufacturing offers a low-emission, waste-minimizing pathway that aligns with net-zero targets and circular economy models. On the regulatory front, faster approval pathways for biologics and biosimilars, along with government grants and tax incentives, are lowering barriers to entry for startups and accelerating innovation. Advances in automation, process control, and modular facility design are reducing time-to-market and enabling flexible production capable of meeting both large-scale and niche demands. Additionally, increasing collaboration between academia, biotech companies, and multinational manufacturers is creating innovation clusters and accelerating the development of next-generation platforms. As more industries and governments recognize the strategic value of biological manufacturing, investment and innovation in this field are set to continue rising. The result is a dynamic, expanding market with the potential to redefine global production norms-where biology becomes the engine of industry.

SCOPE OF STUDY:

The report analyzes the Biomanufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Workflow (Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing, Downstream Biomanufacturing); End-Use (BioPharmaceuticals Companies End-Use, Research Institutions End-Use, CMOs / CDMOs End-Use); Application (Monoclonal Antibodies Application, Hormones Application, Vaccines Application, Recombinant Proteins Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• AbbVie Inc.
• Amgen Inc.
• Biocon Limited
• BioNTech SE
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Catalent, Inc.
• Cytiva
• Eli Lilly and Company
• FUJIFILM Diosynth Biotechnologies
• Genentech, Inc.
• Ginkgo Bioworks Holdings, Inc.
• Lonza Group AG
• Moderna, Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Roche Holding AG
• Samsung Biologics Co., Ltd.
• WuXi Biologics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Biomanufacturing - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Demand for Biologics and Cell Therapies Throws the Spotlight on Scalable Biomanufacturing Platforms
  • Expansion of Monoclonal Antibody Production Spurs Growth in Flexible and High-Throughput Bioprocessing Systems
  • Here's How Personalized Medicine Is Driving the Need for Agile and Modular Biomanufacturing Facilities
  • Increased Focus on Pandemic Preparedness and Vaccine Supply Chains Strengthens the Business Case for Regional Biomanufacturing Hubs
  • Continuous Processing Technologies Propel Efficiency and Reduce Costs in Biologics Manufacturing
  • Single-Use Bioreactors and Disposable Systems Accelerate Time-to-Market and Reduce Contamination Risks
  • Adoption of Digital Twins and AI-Powered Process Analytics Drives Smart and Predictive Biomanufacturing
  • Here's the Story: How Contract Development and Manufacturing Organizations (CDMOs) Are Reshaping Global Capacity
  • Globalization of Cell and Gene Therapy Trials Expands the Addressable Market for Advanced Biomanufacturing Platforms
  • Integration of PAT and QbD Principles Enhances Regulatory Compliance and Product Consistency
  • Automation and Robotics in Upstream and Downstream Processes Fuel Workforce Efficiency and Scalability
  • Biomanufacturing's Role in mRNA Therapeutics and Next-Gen Vaccines Creates Long-Term Strategic Opportunity
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Biomanufacturing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Biomanufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Biomanufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Biomanufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Continuous Upstream Biomanufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Continuous Upstream Biomanufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Continuous Upstream Biomanufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Single-Use Upstream Biomanufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Single-Use Upstream Biomanufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Single-Use Upstream Biomanufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Downstream Biomanufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Downstream Biomanufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Downstream Biomanufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Recombinant Proteins Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Recombinant Proteins Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Recombinant Proteins Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Monoclonal Antibodies Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Monoclonal Antibodies Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Monoclonal Antibodies Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hormones Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hormones Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Hormones Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Vaccines Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Vaccines Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Vaccines Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for BioPharmaceuticals Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for BioPharmaceuticals Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for BioPharmaceuticals Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Research Institutions End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Research Institutions End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Research Institutions End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for CMOs / CDMOs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for CMOs / CDMOs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for CMOs / CDMOs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: USA 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: USA 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: Canada 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Canada 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• JAPAN
  • Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: Japan 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: Japan 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• CHINA
  • Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: China 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: China 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: China 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• EUROPE
  • Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Biomanufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Biomanufacturing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Biomanufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: Europe 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: Europe 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• FRANCE
  • Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: France 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: France 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: France 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• GERMANY
  • Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Germany 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Germany 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: Italy 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: Italy 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: UK 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: UK 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: Spain 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Spain 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Spain 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Russia 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Russia 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Russia 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Biomanufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Biomanufacturing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Biomanufacturing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Australia 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: Australia 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: Australia 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• INDIA
  • Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: India 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: India 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: India 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: South Korea 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: South Korea 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: South Korea 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Biomanufacturing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Biomanufacturing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Biomanufacturing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Latin America 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Latin America 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Argentina 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Argentina 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Argentina 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Brazil 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Brazil 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Brazil 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: Mexico 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: Mexico 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: Mexico 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Biomanufacturing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Biomanufacturing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Biomanufacturing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Middle East 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Middle East 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Iran 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Iran 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Iran 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Israel 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Israel 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Israel 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: UAE 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: UAE 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: UAE 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030
• AFRICA
  • Biomanufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Biomanufacturing by Workflow - Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Africa 16-Year Perspective for Biomanufacturing by Workflow - Percentage Breakdown of Value Sales for Continuous Upstream Biomanufacturing, Single-Use Upstream Biomanufacturing and Downstream Biomanufacturing for the Years 2014, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Biomanufacturing by Application - Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 307: Africa 16-Year Perspective for Biomanufacturing by Application - Percentage Breakdown of Value Sales for Recombinant Proteins Application, Other Applications, Monoclonal Antibodies Application, Hormones Application and Vaccines Application for the Years 2014, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Biomanufacturing by End-Use - BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 310: Africa 16-Year Perspective for Biomanufacturing by End-Use - Percentage Breakdown of Value Sales for BioPharmaceuticals Companies End-Use, Research Institutions End-Use and CMOs / CDMOs End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION